首页 | 本学科首页   官方微博 | 高级检索  
     


Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme
Authors:Toby A. Eyre  Christopher P. Fox  Ali Boden  Adrian Bloor  Moez Dungawalla  Paneesha Shankara  Richard Went  Anna H. Schuh
Affiliation:1. Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK;2. Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK;3. Department of Haematology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK;4. Department of Haematology, The Christie Hospital NHS Trust, Manchester, UK;5. Department of Haematology, Milton Keynes Hospital, Milton Keynes, UK;6. Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK;7. Department of Clinical Haematology, The Rotherham NHS Foundation Trust, Rotherham, UK;8. Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK

NIHR BRC Oxford Molecular Diagnostic Centre, Oxford University Hospitals NHS Trust and Department of Oncology, University of Oxford, John Radcliffe Hospital, Oxford, UK

Abstract:
Keywords:idelalisib  TP53 deletion, TP53  B-PLL  prolymphocytic leukaemia
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号